JP5419455B2 - 自己免疫疾患治療のための乳酸菌の使用 - Google Patents

自己免疫疾患治療のための乳酸菌の使用 Download PDF

Info

Publication number
JP5419455B2
JP5419455B2 JP2008534491A JP2008534491A JP5419455B2 JP 5419455 B2 JP5419455 B2 JP 5419455B2 JP 2008534491 A JP2008534491 A JP 2008534491A JP 2008534491 A JP2008534491 A JP 2008534491A JP 5419455 B2 JP5419455 B2 JP 5419455B2
Authority
JP
Japan
Prior art keywords
cells
use according
day
treatment
paracasei
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008534491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511471A (ja
Inventor
ジャン アレンフォール
アンナ ベルゲン
キャロル ラスク
アグネス ウォルド
シャハラン アガイベイク−ラバサーニ
Original Assignee
プロビ エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロビ エービー filed Critical プロビ エービー
Publication of JP2009511471A publication Critical patent/JP2009511471A/ja
Application granted granted Critical
Publication of JP5419455B2 publication Critical patent/JP5419455B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/40—Products characterised by the type, form or use
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/02—Products made from whole meal; Products containing bran or rough-ground grain
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/06—Products with modified nutritive value, e.g. with modified starch content
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/24—Organic nitrogen compounds
    • A21D2/26—Proteins
    • A21D2/267—Microbial proteins
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D8/00—Methods for preparing or baking dough
    • A21D8/02—Methods for preparing dough; Treating dough prior to baking
    • A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
    • A21D8/045—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes with a leaven or a composition containing acidifying bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/857—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
JP2008534491A 2005-10-06 2006-10-06 自己免疫疾患治療のための乳酸菌の使用 Expired - Fee Related JP5419455B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0502209-0 2005-10-06
SE0502209 2005-10-06
SE0502250 2005-10-07
SE0502250-4 2005-10-07
PCT/SE2006/001139 WO2007040446A1 (en) 2005-10-06 2006-10-06 Use of lactobacillus for treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2009511471A JP2009511471A (ja) 2009-03-19
JP5419455B2 true JP5419455B2 (ja) 2014-02-19

Family

ID=37906406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008534491A Expired - Fee Related JP5419455B2 (ja) 2005-10-06 2006-10-06 自己免疫疾患治療のための乳酸菌の使用
JP2008534490A Active JP5792919B2 (ja) 2005-10-06 2006-10-06 ウイルス感染治療のための乳酸菌の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008534490A Active JP5792919B2 (ja) 2005-10-06 2006-10-06 ウイルス感染治療のための乳酸菌の使用

Country Status (18)

Country Link
US (3) US8420376B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1951273B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5419455B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR101300077B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2006297895B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BRPI0616962B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2625074C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1118006T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1951273T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2590916T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE030542T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (2) IN2008DE02592A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT1951272T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL1951273T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1951272T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2440123C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1951272T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (3) WO2007040446A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5019961B2 (ja) * 2006-06-26 2012-09-05 株式会社ヤクルト本社 インターロイキン１０産生促進剤
DK2068899T3 (da) 2006-10-02 2015-09-28 Dupont Nutrition Biosci Aps Lactobacillus acidophilus til anvendelse til reducering af forekomsten og varigheden af luftvejsinfektioner
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
JP2009057346A (ja) * 2007-09-03 2009-03-19 Kirin Holdings Co Ltd 免疫バランス調節用組成物
FR2922450B1 (fr) * 2007-10-19 2014-06-13 Lallemand Sas Utilisation de bacteries lactique pour la prevention et/ou le traitement de pathologies cutanees
WO2009062132A2 (en) 2007-11-09 2009-05-14 California Institute Of Technology Immunomodulating compounds and related compositions and methods
EP2153837A1 (en) * 2008-08-14 2010-02-17 Compagnie Gervais Danone Compositions comprising Lactobacillus casei for improving resistance to common infectious diseases
SE533778C2 (sv) 2009-05-14 2011-01-11 Probi Ab Probiotisk fruktdryck
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2011059332A2 (en) 2009-11-16 2011-05-19 Stichting Top Institute Food And Nutrition Improved immunomodulation by probiotics
KR20110082480A (ko) * 2010-01-11 2011-07-19 포항공과대학교 산학협력단 포유동물 체내에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
BR112012018813B1 (pt) * 2010-01-28 2020-12-08 Ab-Biotics S.A. composição compreendendo cepas bacterianas com atividade anti-inflamatória, imunomoduladora, antiibs ou antidistensão abdominal, uso das mesmas, bem como produtos farmacêutico, veterinário e comestível compreendendo a referida composição
DK2555753T3 (en) 2010-04-07 2018-11-26 California Inst Of Techn Vesicle for delivering a compound to a mucosal membrane as well as corresponding compositions, methods and systems
EP2571982A4 (en) 2010-05-20 2014-01-01 California Inst Of Techn ANTIGEN-SPECIFIC TREGS AND CORRESPONDING COMPOSITIONS, METHODS AND SYSTEMS
WO2012081650A1 (ja) * 2010-12-16 2012-06-21 株式会社明治 遅延型過敏症軽減剤
CN103261165B (zh) 2010-12-23 2015-08-26 辉瑞公司 胰高血糖素受体调节剂
WO2012093755A1 (ko) * 2011-01-04 2012-07-12 포항공과대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
KR101585840B1 (ko) 2011-02-08 2016-01-15 화이자 인코포레이티드 글루카곤 수용체 조절자
WO2012133827A1 (ja) * 2011-03-31 2012-10-04 森永乳業株式会社 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料
WO2012141540A2 (ko) * 2011-04-13 2012-10-18 씨제이제일제당 (주) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
KR101279852B1 (ko) * 2011-06-29 2013-07-09 주식회사 쎌바이오텍 골다공증 예방 또는 치료용 조성물
JP6273200B2 (ja) 2011-07-12 2018-01-31 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 脂質含有ｐｓａ組成物、その単離の方法および使用の方法
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
JP5468183B2 (ja) 2011-12-28 2014-04-09 株式会社山田養蜂場本社 ＩｇＡ産生促進作用を有する新規乳酸菌及びその用途
JP6028962B2 (ja) * 2012-02-16 2016-11-24 国立大学法人金沢大学 ウイルス感染予防乳酸菌組成物及びウイルス感染予防乳酸発酵食品
JP5995593B2 (ja) * 2012-08-02 2016-09-21 丸善製薬株式会社 抗炎症剤
WO2014038929A1 (en) 2012-09-07 2014-03-13 N.V. Nutricia Probiotics for producing antiviral factors
FR2997960B1 (fr) * 2012-11-09 2016-08-05 Inst Nat De La Rech Agronomique (Inra) Nouvelle souche bacterienne de lactobacillus plantarum et utilisation de cette souche
WO2014077365A1 (ja) 2012-11-16 2014-05-22 カルピス株式会社 特定のラクトバチルス・ガセリ株又はその処理物を含有するストレス性腸障害の軽減剤
CN117064923A (zh) * 2013-04-03 2023-11-17 普罗比公司 益生菌菌株用于治疗或预防骨质疏松
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
KR101614262B1 (ko) * 2013-07-12 2016-04-20 모리나가 뉴교 가부시키가이샤 신규 유산균, 그리고 신규 유산균을 함유하는 의약, 음식품 및 사료
TWI505831B (zh) * 2013-11-15 2015-11-01 Genmont Biotech Inc 用於治療微小核糖核酸病毒感染的益生菌組合物及其用途
TWI505832B (zh) 2014-02-21 2015-11-01 Genmont Biotech Inc 乳酸菌、其組合物與彼等於治療自體免疫疾病暨其倂發症之用途
KR101644595B1 (ko) * 2014-07-11 2016-08-03 한국식품연구원 락토바실러스 파라카제이(Lactobacillus paracasei)를 유효성분으로 포함하는 Ｔｈ1-매개 면역 질환 또는 Ｔｈ2-매개 면역 질환의 예방, 개선 또는 치료용 조성물
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
KR101749222B1 (ko) * 2016-01-04 2017-06-21 주식회사 카브 젖산균을 유효성분으로 포함하는 인플루엔자 바이러스 예방 및 치료용 조성물
KR102852714B1 (ko) * 2016-01-19 2025-08-29 시므라이즈 아게 구강 내 항-염증제로서 프로바이오틱스의 용도
GB201600975D0 (en) 2016-01-19 2016-03-02 Probi Ab Novel strain of probiotic bacteria and compositions and uses thereof
EP3196318A1 (en) 2016-01-19 2017-07-26 Symrise AG Probiotics for altering the composition of oral biofilms
EP3222282A1 (en) * 2016-03-21 2017-09-27 Bionou Research, S.L. Use of probiotics in the treatment and/or prevention of psoriasis
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN106562462A (zh) * 2016-11-04 2017-04-19 覃贤强 一种富硒保健汤圆及其制备方法
EP3568144B1 (en) * 2017-01-12 2024-05-08 Probi Ab Probiotic compositions and uses thereof
EP3351259A1 (en) 2017-01-18 2018-07-25 Symrise AG Probiotics for aggregation with disease-associated species in the oral cavity
EP3578637A4 (en) * 2017-01-31 2020-12-16 University - Industry Cooperation Group of Kyung Hee University NEW LACTIC BACTERIA AND THEIR USE
JP6839298B2 (ja) * 2017-01-31 2021-03-03 ユニバーシティ−インダストリー コーオペレイション グループ オブ キョンヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ 新規乳酸菌およびその用途
GB201709763D0 (en) * 2017-06-19 2017-08-02 Probi Ab Biological materials and methods
JP6942030B2 (ja) * 2017-11-02 2021-09-29 株式会社ヤクルト本社 抗アレルギー剤感受性判定マーカー
SG10202112104UA (en) 2018-05-09 2021-12-30 Ko Biolabs Inc Lactobacillus paracasei strain and use thereof
JP7088573B2 (ja) 2018-05-23 2022-06-21 コバイオラブズ・インコーポレイテッド ラクトバチルス・ガッセリーｋｂｌ６９７株及びその使用
KR20210024014A (ko) * 2018-06-18 2021-03-04 프로비 에이비 프로바이오틱스 조성물 및 이의 용도
KR102770563B1 (ko) * 2018-06-18 2025-02-21 프로비 에이비 락토바실러스 플란타룸 조성물 및 이의 용도
WO2020001747A1 (en) 2018-06-26 2020-01-02 Symrise Ag Lactobacillus plantarum for skin care
WO2020084051A1 (en) 2018-10-24 2020-04-30 Novozymes A/S Probiotic supplement for metabolic health comprising lactobacillus
US11058634B2 (en) 2018-11-19 2021-07-13 Steven J. Edwards Adherent oral pharmabiotic delivery strip
WO2020118576A1 (zh) * 2018-12-12 2020-06-18 生合生物科技股份有限公司 胚芽乳酸杆菌twk10在制备抗运动后发炎或降体脂组合物的用途
GB201905386D0 (en) * 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
IT201900013740A1 (it) * 2019-08-01 2021-02-01 Nutrilinea S R L Composition comprising S-adenosyl-L-methionine and a probiotic for use to treat depression
JP7195714B2 (ja) * 2020-10-19 2022-12-26 曽根ファーム株式会社 炎症性腸疾患用組成物
CN111035663B (zh) * 2020-01-17 2023-07-14 广州医科大学附属口腔医院（广州医科大学羊城医院） 酸鱼乳杆菌10851在制备治疗多发性硬化的药物中的应用
IT202000007675A1 (it) * 2020-04-09 2021-10-09 Sofar Spa Ivermectina e sue composizioni per uso nel trattamento di infezioni da coronavirus principalmente a carico dell’apparato respiratorio
EP4159839A4 (en) 2020-05-29 2024-10-23 Tohoku University ANTIVIRAL AGENT
CN116133669A (zh) * 2020-06-06 2023-05-16 群体创新有限责任公司 用于抑制包括冠状病毒感染的病毒感染的材料和方法
KR20220091427A (ko) 2020-12-23 2022-06-30 주식회사 리스큐어바이오사이언시스 락토바실러스 사케아이 유래 세포밖 소포체를 유효성분으로 포함하는 자가면역질환의 개선, 예방 또는 치료용 조성물
JP7594980B2 (ja) 2021-06-22 2024-12-05 株式会社ヤクルト本社 単純ヘルペスウイルスの再活性化抑制用組成物
CN114085798B (zh) * 2021-12-28 2023-10-31 杭州普元生物技术有限公司 一种植物乳杆菌及其在预防和/或治疗疾病中的应用
CN114317343A (zh) * 2021-12-28 2022-04-12 杭州普元生物技术有限公司 一种植物乳杆菌及其在预防和/或治疗中枢神经系统疾病中的应用
CN116270763A (zh) * 2023-04-04 2023-06-23 广东南芯医疗科技有限公司 发酵乳杆菌e15在制备预防或治疗肠道炎症药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983163A (en) * 1981-10-09 1991-01-08 Science Research Center, Inc. Method, compositions and articles for prevention and treatment of herpes simplex virus infections
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
JP4064481B2 (ja) 1996-10-11 2008-03-19 ハウスウェルネスフーズ株式会社 免疫賦活剤
JP4163276B2 (ja) * 1998-02-05 2008-10-08 独立行政法人理化学研究所 機能性組成物
AU764011B2 (en) * 1998-10-01 2003-08-07 Probi Ab Reduction of oxidative stress factors
EP1020123A1 (en) * 1999-01-18 2000-07-19 Sitia-Yomo S.p.A. Beverages containing live lactic bacteria
EP1034787A1 (en) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
RO121700B1 (ro) * 1999-03-11 2008-02-28 Societe Des Produits Nestle S.A. Bacterii lactobacillus capabile să prevină diareea cauzată de bacterii patogene şi rotavirusuri
IT1306716B1 (it) * 1999-06-21 2001-10-02 Mendes S U R L Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
EP1084709A1 (en) * 1999-09-17 2001-03-21 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Oral recombinant lactobacilli vaccines
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
SE0003045D0 (sv) * 2000-08-29 2000-08-29 Probi Ab New method
SE0003100D0 (sv) * 2000-09-01 2000-09-01 Probi Ab New strains
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
WO2003022255A2 (en) 2001-09-05 2003-03-20 Vsl Pharmaceuticals, Inc. Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy
RU2223774C2 (ru) * 2002-04-11 2004-02-20 Закрытое акционерное общество "Партнер" Способ коррекции дисбиотических расстройств у детей раннего возраста с диареями
US20040022775A1 (en) * 2002-04-15 2004-02-05 Gregor Reid Methods of treating viral infections in mammals
RU2247148C2 (ru) * 2002-05-28 2005-02-27 Пименов Евгений Васильевич Штамм бактерий lactobacillus plantarum p4, штамм бактерий lactobacillus buchneri p0 и препарат-пробиотик на их основе для коррекции дисбактериозов различной этиологии у людей и животных
US20040002275A1 (en) * 2002-06-28 2004-01-01 Niranjan Thakore Fabric reinforced rubber product
JP4034632B2 (ja) * 2002-10-01 2008-01-16 ハウスウェルネスフーズ株式会社 乳酸菌含有炊飯用組成物
SE526711C2 (sv) * 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
WO2004076615A2 (en) 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
WO2004103083A1 (en) * 2003-05-22 2004-12-02 Synbiotics Ab A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and a fiber fermenting property
AU2003247193A1 (en) * 2003-07-23 2005-02-04 M.D.Lab Corp. Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus
ES2356315T3 (es) * 2003-08-21 2011-04-06 Otsuka Pharmaceutical Co., Ltd. Bacterias ácido-lácticas que presentan un efecto de inmunopotenciación de las mucosas.
RU2258524C2 (ru) * 2003-10-23 2005-08-20 Закрытое акционерное общество "Партнер" Композиция для лечения острых респираторных заболеваний hib-этиологии у детей и способ лечения
SE0400355D0 (sv) * 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
CN101128182B (zh) * 2004-11-25 2011-11-16 荷兰联合利华有限公司 重链和结构域抗体

Also Published As

Publication number Publication date
PL1951272T3 (pl) 2016-12-30
US20100034877A1 (en) 2010-02-11
US20090208469A1 (en) 2009-08-20
BRPI0616962A2 (pt) 2011-07-05
US8936783B2 (en) 2015-01-20
EP1951272A1 (en) 2008-08-06
KR20080080981A (ko) 2008-09-05
PL1951273T3 (pl) 2014-07-31
BRPI0616962B8 (pt) 2021-05-25
KR101300077B1 (ko) 2013-08-30
RU2008118007A (ru) 2009-11-20
EP1951272A4 (en) 2010-01-27
KR20080081146A (ko) 2008-09-08
US8691214B2 (en) 2014-04-08
KR101300086B1 (ko) 2013-08-30
EP1951273A1 (en) 2008-08-06
US20130017261A1 (en) 2013-01-17
ES2590916T3 (es) 2016-11-24
EP1951272B1 (en) 2016-06-15
BRPI0616960B8 (pt) 2021-05-25
PT1951272T (pt) 2016-09-20
DK1951273T3 (da) 2014-05-05
JP5792919B2 (ja) 2015-10-14
CA2625074A1 (en) 2007-04-12
BRPI0616960B1 (pt) 2019-10-08
ES2460891T3 (es) 2014-05-14
AU2006297895A1 (en) 2007-04-12
AU2006297896A1 (en) 2007-04-12
JP2009511471A (ja) 2009-03-19
CA2624660A1 (en) 2007-04-12
RU2440123C2 (ru) 2012-01-20
JP2009511470A (ja) 2009-03-19
US8420376B2 (en) 2013-04-16
WO2007040446A1 (en) 2007-04-12
RU2417092C2 (ru) 2011-04-27
EP1951273A4 (en) 2010-02-17
AU2006297896B2 (en) 2011-12-08
IN2008DE02592A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2008-07-04
SI1951272T1 (sl) 2016-10-28
CA2625074C (en) 2016-05-10
HUE030542T2 (en) 2017-05-29
RU2008118008A (ru) 2009-11-20
WO2007040444A1 (en) 2007-04-12
LT1951272T (lt) 2016-10-10
IN2008DE02606A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2008-07-04
AU2006297895B2 (en) 2011-09-01
WO2007040445A1 (en) 2007-04-12
BRPI0616960A2 (pt) 2011-07-05
DK1951272T3 (en) 2016-09-19
CA2624660C (en) 2016-07-12
EP1951273B1 (en) 2014-02-12
CY1118006T1 (el) 2017-05-17
BRPI0616962B1 (pt) 2019-09-17

Similar Documents

Publication Publication Date Title
JP5419455B2 (ja) 自己免疫疾患治療のための乳酸菌の使用
CN101325960B (zh) 乳酸杆菌用于治疗自身免疫性疾病的用途
Sharma et al. Probiotics: a comprehensive approach toward health foods
Ruemmele et al. Clinical evidence for immunomodulatory effects of probiotic bacteria
JP5868843B2 (ja) 乳酸菌含有製剤
Kim et al. Dietary supplementation of probiotic Bacillus polyfermenticus, Bispan strain, modulates natural killer cell and T cell subset populations and immunoglobulin G levels in human subjects
CN101171019A (zh) 免疫功能调节剂
WO2018047930A1 (ja) 眼疲労の抑制又は改善用組成物
Kumar Korada et al. Can probiotics cure inflammatory bowel diseases?
US8980289B2 (en) Intestine immunomodulator
Sako et al. The world’s oldest probiotic: perspectives for health claims
Özdemir Mechanisms of preventative and therapeutic role of probiotics in different allergic and autoimmune disorders
Kanda et al. Lactic acid bacteria beverage contribution for preventive medicine and nationwide health problems in Japan
Frøkiær Probiotics and the Immune System
Frøkiær 26 Probiotics and the

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120816

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131119

R150 Certificate of patent or registration of utility model

Ref document number: 5419455

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees